Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy

NCT00878722 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: PXD101
DRUG: idarubicin

Sponsor

Valerio Therapeutics